On the stock market since 2020, it operates in the world of health and science. It has 206 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Debt is low and cash is strong; the finances stand solid.
Clearly below the class average.
Clearly below the class average.
The stock has been running stronger than the market lately.
Growth: Sales growth trails the sector average.
Business Quality: Profit power and business quality trail similar companies in the sector.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: Right now the product sells for less than it costs to make; every sale deepens the loss.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Sales run at $6.9M a year. A small number, but proof the product has real buyers.
There is $653.5M in the vault; even if every debt were paid off, $649.6M would remain.
The average analyst price target is $35.25 — 26% above today’s price.
A loss of $212.4M against $6.9M in annual sales. And on top of that, sales fell from the year before.
This stock swings about 2.1 times as much as the market average. Big rallies — and big drops — can both happen fast.
On our five-subject report card, IMNM sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: IMNM is a high-risk stock — not yet profitable, and its future rides on its product catching on.
Analysts’ average target sits above today’s price, yet the valuation grade (45/100) says the stock isn’t cheap.